• 1
    Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, et al. The risk of transmission of hepatitis B from HBsAg (−), HBcAb (+), HBIgM (−) organ donors. Transplantation 1995; 59: 230234.
  • 2
    Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113: 16681674.
  • 3
    Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26: 517526.
  • 4
    Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 15: 15821584.
  • 5
    Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494499.
  • 6
    Burton JR, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003; 9: 837842.
  • 7
    Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48( suppl 2): S2S19.
  • 8
    United Network for Organ Sharing. Available at: Accessed October 2008.
  • 9
    Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Gunther S, et al. Serological pattern “anti-HBc alone”: report on a workshop. J Med Virol 2000; 62: 450455.
  • 10
    Douglas DD, Rakela J, Wright TL, Krom RAF, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3: 105111.
  • 11
    Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan C-K, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transpl 2001; 6: 513517.
  • 12
    Chen Y-S, Wang C-C, de Villa VH, Wang S-H, Cheng Y-F, Huang T-L, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16: 405409.
  • 13
    Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75: 11791186.
  • 14
    Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core antibody-positive donors. Clin Transplant 2006; 20: 369373.
  • 15
    Jain A, Orloff M, Abt P, Kashyap R, Mohanka R, Lansing K, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005; 37: 31873189.
  • 16
    Yen RD, Bonnati H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006; 6: 10771083.
  • 17
    Luo K-X, Zhou R, He C, Liang Z-S, Jiang S. Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen. J Med Virol 1991; 35: 5559.
  • 18
    Yotsuyanagi H, Yashuda K, Moriya K, Shintani Y, Fugie H, Tsutsumi T, et al. Frequent presence of HBV in the sera of HBsAg-negative, anti-HBc-positive blood donors. Transfusion 2001; 41: 10931099.
  • 19
    Alhababi F, Sallam TA, Tong CYW. The significance of ‘anti-HBc only’ in the clinical virology laboratory. J Clin Virol 2003; 27: 162169.
  • 20
    Douglass DD, Taswell HF, Rakela J, Rabe D. Absence of hepatitis B virus DNA detected by polymerase chain reaction in blood donors who are hepatitis B surface antigen negative and antibody to hepatitis B core antigen positive from a United States population with a low prevalence of hepatitis B serologic markers. Transfusion 1993; 33: 212216.
  • 21
    Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, Naoumov NV. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003; 77: 88828892.
  • 22
    Roche B, Roque-Afonso AM, Antonini T, Gigou M, Castaing D, Samuel D. Risk of HBV transmission in recipients of liver graft from HBc antibody positive donors using HBIg mono-prophylaxis [abstract 71]. J Hepatol 2008; 48; S31.
  • 23
    Perrillo RP, Parker ML, Campbell C, Sanders GE, Strang SP, Regenstein F. Prevaccination screening of medical and dental students. Should low levels of antibody to hepatitis B surface antigen preclude vaccination? JAMA 1983; 250: 24812484.
  • 24
    Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wiesner RH, Douglas DD. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003; 9: 1215311257.
  • 25
    Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl 2004; 10: 356362.
  • 26
    Shetty K, Hussain M, Nei L, Reddy KR, Lok ASF. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 2008; 14: 534540.
  • 27
    Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999; 318: 304307.
  • 28
    Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003; 17: 254258.
  • 29
    Gane EJ, Angus PW, Strasser S, Crawford DHG, Ring J, Jeffrey GP, McCaughan GW. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931937.